Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026 [Yahoo! Finance]
Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026
Bioventus (NASDAQ:BVS) was upgraded by analysts at Barrington Research to a "strong-buy" rating.
Bioventus (NYSE:BVS) is now covered by analysts at Barrington Research. They set an "outperform" rating and a $13.00 price target on the stock.
Bioventus Details Turnaround Plan, Four Growth Drivers at J.P. Morgan Conference [Yahoo! Finance]